|
PT2595980E
(pt)
|
2010-07-22 |
2014-11-27 |
Gilead Sciences Inc |
Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
|
|
KR20160148715A
(ko)
*
|
2014-05-13 |
2016-12-26 |
에프. 호프만-라 로슈 아게 |
B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
|
|
TWI740546B
(zh)
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
HK1244281B
(zh)
*
|
2015-02-11 |
2020-02-07 |
F. Hoffmann-La Roche Ag |
治疗和预防乙型肝炎病毒感染的2-氧代-6，7-二氢苯并[a]喹嗪-3-甲酸衍生物
|
|
EP3292120B1
(en)
|
2015-05-04 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
JP6506880B2
(ja)
|
2015-07-27 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
|
|
WO2017017043A1
(en)
|
2015-07-28 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
|
|
PL3349758T3
(pl)
|
2015-09-16 |
2022-09-12 |
Gilead Sciences, Inc. |
Sposoby leczenia zakażeń wirusami arenaviridae
|
|
US9845325B2
(en)
|
2016-02-19 |
2017-12-19 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
EP3426245B1
(en)
|
2016-03-07 |
2022-12-14 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
BR102017010009A2
(pt)
*
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
MX2018014377A
(es)
|
2016-05-27 |
2019-03-14 |
Gilead Sciences Inc |
Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
|
|
EP3468561A4
(en)
|
2016-06-10 |
2019-12-04 |
Enanta Pharmaceuticals, Inc. |
ANTIVIRAL AGENTS AGAINST HEPATITIS B
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
MA45496A
(fr)
*
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
WO2018011162A1
(en)
*
|
2016-07-14 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
|
CN110240596B
(zh)
*
|
2016-07-29 |
2020-09-11 |
新波制药有限公司 |
用于治疗hbv感染的治疗剂
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018041873A1
(en)
*
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
US10370342B2
(en)
|
2016-09-02 |
2019-08-06 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
|
PE20191353A1
(es)
|
2016-10-14 |
2019-10-01 |
Prec Biosciences Inc |
Meganucleasas disenadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b
|
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
|
EP3535261B1
(en)
|
2016-11-03 |
2020-08-05 |
F. Hoffmann-La Roche AG |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
JP7019692B2
(ja)
|
2016-11-03 |
2022-02-15 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染の治療又は予防のための新規テトラヒドロイソキノリン類とテトラヒドロナフチリジン類
|
|
CN110088103B
(zh)
|
2016-11-03 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶化合物
|
|
AU2017353986B2
(en)
*
|
2016-11-07 |
2021-08-19 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
|
CN109369640B
(zh)
*
|
2017-01-13 |
2020-03-27 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物的制备方法
|
|
TWI784370B
(zh)
|
2017-01-31 |
2022-11-21 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
KR102085497B1
(ko)
*
|
2017-02-23 |
2020-03-05 |
푸젠 코선터 파마슈티컬 컴퍼니 리미티드 |
트리사이클릭 화합물 및 이의 응용
|
|
KR102460968B1
(ko)
|
2017-03-14 |
2022-11-01 |
길리애드 사이언시즈, 인코포레이티드 |
고양이 코로나바이러스 감염의 치료 방법
|
|
EP3601216B1
(en)
|
2017-03-21 |
2023-10-25 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
AR111419A1
(es)
*
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
JP2020518578A
(ja)
|
2017-05-01 |
2020-06-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
（Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
|
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
|
CN110066278B
(zh)
*
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
CA3077489A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
|
UY37861A
(es)
|
2017-08-28 |
2019-03-29 |
Enanta Pharm Inc |
Agentes antivirales contra la hepatitis b
|
|
HUE061380T2
(hu)
*
|
2017-10-05 |
2023-06-28 |
Glaxosmithkline Ip Dev Ltd |
Kémiai vegyületek
|
|
CR20210262A
(es)
|
2017-10-16 |
2022-06-27 |
Hoffmann La Roche |
MOLÉCULA DE ÁCIDOS NUCLEICOS PARA LA REDUCCIÓN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÓN DE LA HEPATITIS B (DIVISIONAL DEL EXPEDIENTE 2020-0205)
|
|
WO2019084271A1
(en)
|
2017-10-25 |
2019-05-02 |
Children's Medical Center Corporation |
PAPD5 INHIBITORS AND METHODS OF USE
|
|
WO2019097479A1
(en)
|
2017-11-17 |
2019-05-23 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
TW201936192A
(zh)
|
2017-12-06 |
2019-09-16 |
美商因那塔製藥公司 |
B 型肝炎抗病毒試劑
|
|
US10428070B2
(en)
|
2017-12-06 |
2019-10-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
|
|
CN111433210A
(zh)
*
|
2017-12-20 |
2020-07-17 |
诺华股份有限公司 |
作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
MX2020006596A
(es)
*
|
2017-12-22 |
2020-09-10 |
Bayer Ag |
Hidroxiisoxazolinas y derivados de estos.
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
CN118084940A
(zh)
|
2018-02-13 |
2024-05-28 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
AU2019223182B2
(en)
|
2018-02-26 |
2021-08-19 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds as HBV replication inhibitors
|
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
TWI801517B
(zh)
|
2018-03-12 |
2023-05-11 |
加拿大商愛彼特生物製藥公司 |
經取代的2-吡啶酮三環化合物、其類似物及其使用方法
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
JP2021521154A
(ja)
|
2018-04-12 |
2021-08-26 |
アービュタス バイオファーマ コーポレイション |
置換ピリジノン含有三環式化合物を調製するための方法
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
AU2019255750B2
(en)
|
2018-04-19 |
2021-10-21 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
SG11202012759XA
(en)
|
2018-07-03 |
2021-01-28 |
Hoffmann La Roche |
Oligonucleotides for modulating tau expression
|
|
PE20210642A1
(es)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores de pd-1/pd-l1
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
WO2020043080A1
(en)
|
2018-08-28 |
2020-03-05 |
Sunshine Lake Pharma Co., Ltd. |
Fused tricyclic compounds and uses thereof in medicine
|
|
UY38383A
(es)
|
2018-09-21 |
2020-04-30 |
Enanta Pharm Inc |
Heterociclos funcionalizados como agentes antivirales
|
|
CN110964023B
(zh)
|
2018-09-30 |
2022-12-27 |
广东东阳光药业有限公司 |
稠合四环类化合物及其在药物中的应用
|
|
CN112955435B
(zh)
|
2018-10-24 |
2024-09-06 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
ES2979163T3
(es)
|
2018-10-31 |
2024-09-24 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
KR102819704B1
(ko)
|
2018-11-21 |
2025-06-11 |
이난타 파마슈티칼스, 인코포레이티드 |
항바이러스제로서의 작용화된 헤테로사이클
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN113999224B
(zh)
*
|
2019-01-08 |
2023-04-07 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
AU2020231115B2
(en)
|
2019-03-07 |
2025-02-20 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
AU2020231201B2
(en)
|
2019-03-07 |
2025-02-20 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
CN113993848A
(zh)
|
2019-04-24 |
2022-01-28 |
儿童医学中心公司 |
Papd5抑制剂及其使用方法
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
US11236111B2
(en)
|
2019-06-03 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US11760755B2
(en)
|
2019-06-04 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
UA129329C2
(uk)
|
2019-06-25 |
2025-03-19 |
Гіліад Сайєнсіз, Інк. |
ЗЛИТІ БІЛКИ FLT3L-Fc
|
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
MX2022003658A
(es)
|
2019-09-30 |
2022-04-25 |
Gilead Sciences Inc |
Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
|
|
DK4069729T3
(da)
|
2019-12-06 |
2025-04-07 |
Prec Biosciences Inc |
Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
|
|
AU2020412875A1
(en)
|
2019-12-24 |
2022-06-23 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN118766947A
(zh)
|
2020-01-27 |
2024-10-15 |
吉利德科学公司 |
用于治疗SARS CoV-2感染的方法
|
|
TWI890963B
(zh)
|
2020-03-12 |
2025-07-21 |
美商基利科學股份有限公司 |
1'-氰基核苷之製備方法
|
|
US11802125B2
(en)
|
2020-03-16 |
2023-10-31 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
AU2021237718B2
(en)
|
2020-03-20 |
2023-09-21 |
Gilead Sciences, Inc. |
Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
CN115362004A
(zh)
|
2020-04-06 |
2022-11-18 |
吉利德科学公司 |
1’-氰基取代的碳核苷类似物的吸入制剂
|
|
EP4151221A4
(en)
*
|
2020-05-15 |
2023-11-15 |
Fujian Akeylink Biotechnology Co., Ltd. |
COMBINATION COMPRISING A TRICYCLIC COMPOUND AND ITS USE IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF HBV
|
|
ES3041698T3
(en)
|
2020-05-29 |
2025-11-13 |
Gilead Sciences Inc |
Remdesivir for the treatment of viral infections
|
|
JP2023531524A
(ja)
|
2020-06-24 |
2023-07-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシド類似体及びその使用
|
|
CN116194144A
(zh)
|
2020-08-07 |
2023-05-30 |
吉利德科学公司 |
膦酰胺核苷酸类似物的前药及其药物用途
|
|
CN111943946B
(zh)
*
|
2020-08-19 |
2022-07-01 |
中国医学科学院医药生物技术研究所 |
含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
|
|
JP7559223B2
(ja)
|
2020-08-24 |
2024-10-01 |
ギリアード サイエンシーズ， インコーポレイテッド |
リン脂質化合物及びその使用
|
|
IL300453A
(en)
|
2020-08-27 |
2023-04-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
EP4346772A1
(en)
|
2021-05-26 |
2024-04-10 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
KR20240023628A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
CN117396478A
(zh)
|
2021-06-23 |
2024-01-12 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
KR20240023629A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
WO2023023527A1
(en)
|
2021-08-18 |
2023-02-23 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
TW202525810A
(zh)
|
2022-03-02 |
2025-07-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
|
CA3243944A1
(en)
|
2022-03-02 |
2023-09-07 |
Gilead Sciences, Inc. |
COMPOUNDS AND METHODS OF TREATMENT FOR VIRAL INFECTIONS
|
|
PE20250419A1
(es)
|
2022-03-03 |
2025-02-14 |
Gilead Sciences Inc |
Compuestos antivirales y metodos de elaboracion y uso de los mismos
|
|
US20230382940A1
(en)
|
2022-03-03 |
2023-11-30 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
JP2025519390A
(ja)
|
2022-06-06 |
2025-06-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法
|
|
EP4547334A1
(en)
|
2022-06-29 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US20240043466A1
(en)
|
2022-06-30 |
2024-02-08 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
EP4665737A1
(en)
|
2023-02-16 |
2025-12-24 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
US20250084088A1
(en)
|
2023-08-31 |
2025-03-13 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
WO2025049699A1
(en)
|
2023-08-31 |
2025-03-06 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
WO2025054278A1
(en)
|
2023-09-06 |
2025-03-13 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
WO2025072641A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|